Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:benefits |
ease of use
improved sensitivity reduced false negatives |
| gptkbp:clinical_trial |
gynecology
results available within days |
| gptkbp:collection |
liquid-based collection
|
| gptkbp:frequency |
every 3 years
|
| https://www.w3.org/2000/01/rdf-schema#label |
BD Sure Path
|
| gptkbp:introduced |
2000s
|
| gptkbp:is_tested_for |
gptkb:HPV_testing
high accuracy report generation improved patient outcomes laboratory analysis reduction in cervical cancer rates collaboration with healthcare providers requires trained personnel specimen collection influence on clinical practice guidelines early detection of cervical cancer less invasive than traditional methods contribution to public health initiatives advancement in cancer screening technology can be combined with HPV testing cytological evaluation cytotechnologist review enhanced screening programs increased awareness of cervical health integration into routine gynecological exams may require follow-up testing not a standalone test provides comprehensive results requires pathologist review role in women's health advocacy support for preventive health measures support for research in cervical cancer |
| gptkbp:is_used_for |
detecting cervical cancer
|
| gptkbp:manufacturer |
gptkb:Becton,_Dickinson_and_Company
|
| gptkbp:marketed_as |
Sure Path
|
| gptkbp:provides_information_on |
ACOG guidelines
ASCCP guidelines |
| gptkbp:recorded_by |
cervical cells
|
| gptkbp:related_to |
Pap smear
|
| gptkbp:storage |
refrigerated
liquid medium |
| gptkbp:target_audience |
women aged 21 and older
|
| gptkbp:technology |
molecular testing
|
| gptkbp:type |
liquid-based cytology
|
| gptkbp:bfsParent |
gptkb:BD_Diagnostics
|
| gptkbp:bfsLayer |
5
|